Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)

v3.24.3
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenues:        
Total revenues, net $ 249 $ 236 $ 249 $ 1,353
Operating expenses:        
Cost of product sales (714) 247 (453) 1,505
Research and development 9,538 1,249 16,254 11,917
Acquired in-process research and development 0 0 27,641 0
General and administrative 4,286 2,490 12,008 7,624
Total operating expenses 13,110 3,986 55,450 21,046
Loss from operations (12,861) (3,750) (55,201) (19,693)
Other income (expense):        
Excess of initial warrant fair value over private placement proceeds 0 0 (79,276) 0
Change in fair value of warrant liability 36,025 0 148,071 0
Private placement transaction costs 0 0 (9,220) 0
Change in fair value of derivative liability (1,100) 100 (6,260) (120)
Interest income (expense), net 964 (1,553) 2,101 (3,498)
Other expense, net (5) (17) (5) (42)
Total other income (expense), net 35,884 (1,470) 55,411 (3,660)
Income (loss) before taxes 23,023 (5,220) 210 (23,353)
Income tax (benefit) expense (14) 8 0 23
Net income (loss) $ 23,037 $ (5,228) $ 210 $ (23,376)
Net loss per share of common stock, basic (in dollars per share) $ 0.98 $ (26.83) [1] $ 0.01 $ (231.05) [1]
Net loss per share of common stock, diluted (in dollars per share) $ (2.83) $ (26.83) [1] $ (22.63) $ (231.05) [1]
Product revenue, net        
Revenues:        
Total revenues, net   $ 236 $ 249 $ 1,353
[1] Amounts for prior periods presented have been retroactively adjusted to reflect the 1-for-240 reverse stock split effected on December 28, 2023. See Note 1 for details.